XML 38 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition and Collaborative Arrangements (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenue Recognition and Collaborative Arrangements        
Total net revenue $ 78,946 $ 64,107 $ 157,624 $ 119,290
Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 68,946 64,107 147,624 119,290
Revenue from collaborative arrangements with a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 10,000 0 10,000 0
GSK        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 78,946 64,107 157,624 119,290
GSK | Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 72,402 67,563 154,536 126,202
Less: amortization of capitalized fees paid to a related party (3,456) (3,456) (6,912) (6,912)
Total net revenue 68,946 64,107 147,624 119,290
GSK | RELVAR/BREO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 45,570 47,086 101,719 89,826
GSK | ANORO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 11,199 10,635 21,049 19,205
GSK | TRELEGY        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 15,633 9,842 31,768 17,171
GSK | Revenue from collaborative arrangements with a related party | Strategic alliance - MABA program        
Revenue Recognition and Collaborative Arrangements        
Total net revenue $ 10,000 $ 0 $ 10,000 $ 0